Anthropic eyes antibiotic breakthrough ahead of IPO
Anthropic is set to reveal a novel antibiotic class targeting resistant bacteria ahead of its IPO, positioning the company at the intersection of AI and biotech. The analysis examines how this potential breakthrough could affect market dynamics, regulatory scrutiny, and the firm’s valuation.
Read Story →
5 min read